JP2023524811A5 - - Google Patents
Info
- Publication number
- JP2023524811A5 JP2023524811A5 JP2022567556A JP2022567556A JP2023524811A5 JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5 JP 2022567556 A JP2022567556 A JP 2022567556A JP 2022567556 A JP2022567556 A JP 2022567556A JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- domain
- antigen
- numbers
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020196P | 2020-05-05 | 2020-05-05 | |
| US63/020,196 | 2020-05-05 | ||
| US202063129718P | 2020-12-23 | 2020-12-23 | |
| US63/129,718 | 2020-12-23 | ||
| US202163147618P | 2021-02-09 | 2021-02-09 | |
| US63/147,618 | 2021-02-09 | ||
| US202163171751P | 2021-04-07 | 2021-04-07 | |
| US63/171,751 | 2021-04-07 | ||
| PCT/US2021/030973 WO2021226289A2 (en) | 2020-05-05 | 2021-05-05 | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524811A JP2023524811A (ja) | 2023-06-13 |
| JP2023524811A5 true JP2023524811A5 (cg-RX-API-DMAC7.html) | 2024-05-15 |
| JP7796044B2 JP7796044B2 (ja) | 2026-01-08 |
Family
ID=78468785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567556A Active JP7796044B2 (ja) | 2020-05-05 | 2021-05-05 | Cd70特異的融合タンパク質を使用したtcrリプログラミングのための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252641A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146233A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7796044B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230020421A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115989033B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021268953A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022353A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177488A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297916A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013956A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021226289A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2021410788A1 (en) * | 2020-12-23 | 2023-08-03 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2025504501A (ja) * | 2022-01-19 | 2025-02-12 | 上海恒潤達生生物科技股▲フン▼有限公司 | 抗cd70ナノボディ及びその応用 |
| WO2023177821A2 (en) * | 2022-03-16 | 2023-09-21 | Myeloid Therapeutics, Inc. | Binding domains and methods of use thereof |
| WO2024249346A1 (en) * | 2023-05-26 | 2024-12-05 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting cd70 expression |
| CN121299119B (zh) * | 2025-12-15 | 2026-03-06 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 噬血细胞综合征克隆性免疫细胞检测试剂组合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2816379A1 (en) * | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| EP3770168A1 (en) * | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| EP3380602A4 (en) * | 2015-11-23 | 2019-09-25 | Trustees of Boston University | METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| EP3583129B1 (en) * | 2017-02-14 | 2021-11-03 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| GB201800649D0 (en) * | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| KR102879284B1 (ko) * | 2018-08-29 | 2025-10-31 | 난징 레전드 바이오테크 씨오., 엘티디. | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 |
| WO2020060593A1 (en) * | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
| WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| WO2022006451A2 (en) * | 2020-07-02 | 2022-01-06 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies |
| AU2021410788A1 (en) * | 2020-12-23 | 2023-08-03 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2022150831A1 (en) * | 2021-01-07 | 2022-07-14 | Innovative Cellular Therapeutics Holdings, Ltd. | Car cells and polyspecific binding molecules for treating solid tumor |
| WO2022192286A1 (en) * | 2021-03-09 | 2022-09-15 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and rna interference |
| WO2022232277A1 (en) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH |
-
2021
- 2021-05-05 WO PCT/US2021/030973 patent/WO2021226289A2/en not_active Ceased
- 2021-05-05 EP EP21799797.2A patent/EP4146233A4/en active Pending
- 2021-05-05 IL IL297916A patent/IL297916A/en unknown
- 2021-05-05 AU AU2021268953A patent/AU2021268953A1/en active Pending
- 2021-05-05 KR KR1020227042681A patent/KR20230020421A/ko not_active Withdrawn
- 2021-05-05 JP JP2022567556A patent/JP7796044B2/ja active Active
- 2021-05-05 MX MX2022013956A patent/MX2022013956A/es unknown
- 2021-05-05 BR BR112022022353A patent/BR112022022353A2/pt not_active Application Discontinuation
- 2021-05-05 CA CA3177488A patent/CA3177488A1/en active Pending
- 2021-05-05 US US17/923,008 patent/US20240252641A1/en active Pending
- 2021-05-05 CN CN202180048074.0A patent/CN115989033B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250092133A1 (en) | Bispecific antibody constructs for cdh3 and cd3 | |
| JP7098629B2 (ja) | 抗pd-1モノクローナル抗体、その製造方法及び用途 | |
| JP6879998B2 (ja) | Cd70及びcd3に対する抗体構築物 | |
| JP6359372B2 (ja) | DARPinを含む二重特異キメラ蛋白質 | |
| TWI769537B (zh) | 標靶bcma的抗體、雙專一性抗體及其用途 | |
| TWI854953B (zh) | 抗cd3抗體及含有該抗體的分子、及其製造方法 | |
| JP2021534762A5 (cg-RX-API-DMAC7.html) | ||
| JP2021510521A5 (cg-RX-API-DMAC7.html) | ||
| JP2022542543A5 (cg-RX-API-DMAC7.html) | ||
| JP2021508469A5 (cg-RX-API-DMAC7.html) | ||
| BR112019016204A2 (pt) | anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d | |
| JP2019533719A5 (cg-RX-API-DMAC7.html) | ||
| AU2016302580A1 (en) | Antibody constructs for FLT3 and CD3 | |
| JP2018502050A5 (cg-RX-API-DMAC7.html) | ||
| CA3131036A1 (en) | Cd3 antigen-binding fragment and application thereof | |
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| WO2022152290A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2023511963A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515560A5 (cg-RX-API-DMAC7.html) | ||
| JP2024535930A5 (cg-RX-API-DMAC7.html) | ||
| WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 | |
| WO2019230869A1 (ja) | 抗ヒトtlr7抗体 | |
| JPWO2011007853A1 (ja) | 癌特異的アイソフォームに対するモノクローナル抗体 | |
| AU2024295542A1 (en) | Anti-fgfr2/pd-1 bispecific antibody | |
| JP7808831B2 (ja) | 抗cd26抗体とその応用 |